Allina Health took part in RSV vaccine clinical trial that Pfizer reports has promising results

[KMSP Fox 9, November 04, 2022]

Pfizer, the pharmaceutical company, recently announced promising phase 3 trial results for a respiratory syncytial virus (RSV) vaccine designed to protect newborns. It plans to submit the vaccine for US Food and Drug Administration approval by the end of the year. Read the Pfizer announcement here.

The announcement comes as young children suffering from RSV are filling local pediatric hospitals. Allina Health took part in the vaccine trial in 2020, with infectious disease specialist Dr. Frank Rhame the lead investigator for the local study. If the FDA approves the RSV vaccine, Rhame says it could be available to the public by late next year. Rhame spoke with FOX 9 News and KSTP-TV about the results of the trial. 

Posted on November 04, 2022 in Vaccine, Infectious Disease